PGA and OncoMRD technology breakthroughs, showing the teeth of OncoDxRxs liquid biopsy umbrella
OncoDxRx integrates PGA drug response prediction and OncoMRD treatment monitoring capabilities.
- (1888PressRelease) August 12, 2024 - The PGA (patient-derived gene expression-informed anticancer drug efficacy) technology has been a cornerstone of OncoDxRx liquid biopsy pipelines since its introduction in 2023, providing the clinicians with a clinical treatment selection capability, thanks to its seamless combination of patient testing with digital data analytics.
The in vitro and in silico combo has been a complex task, since it involved laboratory operation, testing systems, and data computation elements as well, all to allow OncoDxRx to securely handle the patient samples, data and efficiently improve clinical outcomes. PGA inherits the plug-and-play capability from OncoDxRxs core technology.
OncoDxRx, as a prominent liquid biopsy diagnostics company, upholds a formidable and autonomous pipeline strategy known as the exclusiveness-focused development. This key innovation framework is meticulously designed to safeguard technological breakthrough and maintain strategic autonomy. With an arsenal comprising 8 one-of-a-kind technologies, subject to development and commercialization, OncoDxRx executes its novel capabilities through two leading commercially-ready platforms: PGA and OncoMRD (OncoDxRxs monitoring residual disease).
In essence, OncoDxRxs exclusive pipeline is a meticulously orchestrated fusion of expertise, experience and knowhow, underpinned by cutting-edge technology and operational proficiency. By maintaining a diverse array of diagnostics platforms and continuously enhancing its built-for-purpose arsenal, OncoDxRx ensures that its portfolio remains a potent and credible tools for cancer management, safeguarding the companys leading edge and market shares.
OncoDxRx has utilized a clinical study in Taiwan to showcase their two flagship technologies, PGA and OncoMRD, in concerted clinical support. This study included validating a PGA-then-OncoMRD procedure through testing real-world patients. This innovative operational approach was initially experimental but is now on track to become standard practice.
Last year OncoDxRx announced a significant development in gene expression-informed capabilities. The company conducted a testing campaign that incorporated a combined PGA-OncoMRD protocol during this trial. This was achieved by integrating the PGA drug efficacy prediction test with the response monitoring OncoMRD assay. OncoMRD serves multiple functions, such as therapeutic efficacy, patient response, and assessing prognosis and recurrence longitudinally. This integration allows for testing consistency and continuum, reducing variation and delay.
OncoDxRx emphasizes that PGA, along with OncoMRD, complements DNA-based biomarker testing and fills the gaps in precision oncology.
The success of this innovative approach is attributed to the leverage on cell-free mRNA (cfmRNA) core technology, owned by OncoDxRx. The mRNA transcripts are expressed as hundreds of copies and representative of not only tumor itself but also non-tumor microenvironment. This is a significant improvement compared to the tumor-only and diploid nature of DNA biomarkers they replaced.
With 8 one-of-a-kind liquid biopsy technologies, OncoDxRx has accumulated unrivalled experience. After a period of learning and adaptation, the company has broadened the objectives of cfmRNA-powered innovation, dedicating them to cancer diagnostics involving prediction of drug response, monitoring of treatment efficacy, surveillance of relapse, prognosis and early detection.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam